Cargando…

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients

BACKGROUND: Metastatic breast cancer (MBC) prognosis is highly variable, depending on various factors such as the biological subtype, the performance status, disease extension…. A better evaluation of a patient’s prognostic factors could allow for a more accurate choice of treatments. The role of se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darlix, Amélie, Lamy, Pierre-Jean, Lopez-Crapez, Evelyne, Braccini, Antoine Laurent, Firmin, Nelly, Romieu, Gilles, Thezenas, Simon, Jacot, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937557/ https://www.ncbi.nlm.nih.gov/pubmed/27387327 http://dx.doi.org/10.1186/s12885-016-2448-1

Ejemplares similares

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
por: Jacot, William, et al.
Publicado: (2011)

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013)

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
por: Jacot, William, et al.
Publicado: (2015)

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases
por: Braccini, Antoine-Laurent, et al.
Publicado: (2013)

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)

Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study
por: Jacot, William, et al.
Publicado: (2010)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker
por: Papadakos, Konstantinos S., et al.
Publicado: (2019)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner
por: Arsic, Nikola, et al.
Publicado: (2017)

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer
por: Viala, Marie, et al.
Publicado: (2021)

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
por: Bottosso, Michele, et al.
Publicado: (2023)

Correction: The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner
por: Arsic, Nikola, et al.
Publicado: (2017)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
por: Jacot, W, et al.
Publicado: (2004)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
por: Bobrie, Angélique, et al.
Publicado: (2022)

KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues
por: Solassol, Jérome, et al.
Publicado: (2011)

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer
por: El Demery, Mounira, et al.
Publicado: (2014)

Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study
por: Viala, Marie, et al.
Publicado: (2018)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers
por: Chabab, Ghita, et al.
Publicado: (2020)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Poster 100: Evaluation of SS-31 as a Potential Therapeutic in the Treatment of Tendinopathy
por: Szeto, Hazel, et al.
Publicado: (2022)

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Lopez-Crapez, E, et al.
Publicado: (2010)

HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4
por: Tovey, Sian M, et al.
Publicado: (2006)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial
por: Carayol, Marion, et al.
Publicado: (2019)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine
por: Lamy, Pierre-Jean, et al.
Publicado: (2012)

Clinical Value of Serum S100A8/A9 and CA15-3 in the Diagnosis of Breast Cancer
por: Khorrami, Samaneh, et al.
Publicado: (2019)

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis
por: Lopez-Crapez, E, et al.
Publicado: (2005)

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2012)

Carbon Nanopowder-Based Stochastic Sensor for Ultrasensitive Assay of CA 15-3, CEA and HER2 in Whole Blood
por: Stefan-van Staden, Raluca-Ioana, et al.
Publicado: (2022)

Metabolic memory of ß-cells controls insulin secretion and is mediated by CaMKII
por: Santos, Gustavo Jorge dos, et al.
Publicado: (2014)

Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Corbeau, Ileana, et al.
Publicado: (2020)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qtemt6qtvva9kepkk6kafjpv0i